Adamis Pharmaceuticals Corporation announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego, California. Blunt has more than 20 years of experience in the biopharmaceutical and medical device industries. These two new independent board members have replaced Robert B. Rothermel, who has resigned from the Board for personal reasons. Additional information concerning his resignation is contained in a report on Report on Form 8-K that the Company will file with the Securities and Exchange Commission.